Atlas Trials

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT02077166 · COMPLETED

Trial details

NCT number
NCT02077166
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2014-03-13
Primary completion
2020-12-17
Enrollment
138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.